Related Experiment Video
Updated: Mar 23, 2026
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
Published on: August 1, 2025
Dendritic Cells in the Context of Human Tumors: Biology and Experimental Tools
Ilan Volovitz1, Susanne Melzer2,3, Sarah Amar1
1a Cancer Immunotherapy Lab, Neurosurgery Department , Tel-Aviv Medical Center , Tel-Aviv , Israel.
Insights
Dendritic cells (DC), potent antigen-presenting cells (APC), critically influence immune responses in human tumors. Understanding DC subsets and their interactions is key to developing novel cancer therapies.
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- Dendritic cells (DC) are key antigen-presenting cells (APC) that bridge innate and adaptive immunity.
- DCs possess a unique ability to interpret local signals and dictate immune responses, promoting either anti-tumor immunity or immune tolerance.
- This review focuses on the role of human DCs within the tumor microenvironment.
Purpose of the Study:
- To review current knowledge on human dendritic cell biology in the context of cancer.
- To elaborate on the distinct subsets, markers, morphology, and functions of human DCs.
- To discuss advanced methodologies for studying DC-tumor cell interactions.
Main Methods:
- Review of existing literature on human dendritic cell subsets (plasmacytoid and myeloid).
- Discussion of multicolor flow cytometry (FCM) and image-based cytometry (IC) for single-cell analysis.
- Integration of multi-omics data with Immune-Cytomics modeling.
Main Results:
- Human blood contains at least three DC subsets (pDC, mDC), with tissue-specific DCs also existing.
- Different DC subsets exhibit distinct phenotypes and functions, potentially mediating pro- or anti-tumoral effects.
- Advanced techniques enable high-resolution analysis of DC subsets and their interactions with tumor cells.
Conclusions:
- Understanding the diverse roles of DC subsets in human tumors is crucial.
- Integrated approaches combining cytometry, genomics, proteomics, and modeling are vital for deciphering complex DC-tumor interactions.
- Harnessing this knowledge can lead to more effective cancer immunotherapies.
Abstract:
Dendritic cells (DC) are the most potent and versatile antigen-presenting cells (APC) in the immune system. DC have an exceptional ability to comprehend the immune context of a captured antigen based on molecular signals identified from its vicinity. The analyzed information is then conveyed to other immune effector cells. Such capability enables DC to play a pivotal role in mediating either an immunogenic response or immune tolerance towards an acquired antigen. This review summarizes current knowledge on DC in the context of human tumors. It covers the basics of human DC biology, elaborating on the different markers, morphology and function of the different subsets of human DC. Human blood-borne DC are comprised of at least three subsets consisting of one plasmacytoid DC (pDC) and two to three myeloid DC (mDC) subsets. Some tissues have unique DC. Each subset has a different phenotype and function and may induce pro-tumoral or anti-tumoral effects. The review also discusses two methods fundamental to the research of DC on the single-cell level: multicolor flow cytometry (FCM) and image-based cytometry (IC). These methods, along with new genomics and proteomics tools, can provide high-resolution information on specific DC subsets and on immune and tumor cells with which they interact. The different layers of collected biological data may then be integrated using Immune-Cytomics modeling approaches. Such novel integrated approaches may help unravel the complex network of cellular interactions that DC carry out within tumors, and may help harness this complex immunological information into the development of more effective treatments for cancer.
